COVID-19

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

NEW YORK and LONDON, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing…

1 year ago

Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

Updated COVID-19 vaccine effectively targets EG.5, a dominant variant of concern, as well as the rapidly spreading FL 1.5.1 variantUpdated…

1 year ago

72-Provider FQHC Implements eClinicalWorks Population Health Solutions for Improved Screening and Compliance

eClinicalWorks population health solutions streamline patient data for Connecticut Institute for Communities, Inc.WESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, the largest ambulatory cloud EHR,…

1 year ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development…

1 year ago

Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

TARRYTOWN, N.Y., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency…

1 year ago

Nanox Announces Second Quarter of 2023 Financial Results and Provides Business Update

Reports progress towards global supply chain development Ended the second quarter of 2023 with cash, cash equivalents, restricted cash and…

1 year ago

Tonix Pharmaceuticals to Present at the August Virtual Investor Summit

CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products…

1 year ago

Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP E¹ Guidance

-- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million1 ---- FY 2023 Adjusted non-GAAP earnings per…

1 year ago

Advanced Health Intelligence Obtains Overseas R&D Reimbursement Under Australia’s Research and Development Tax Incentive Scheme (R&DTI)

South Perth, Australia--(Newsfile Corp. - August 17, 2023) -  Advanced Health Intelligence Ltd (ASX: AHI) (NASDAQ: AHI) ("AHI" or the…

1 year ago

Oasis Cannabis Dispensary Launches Their New and Improved App to Enhance the Customer Experience

LAS VEGAS, NV / ACCESSWIRE / August 16, 2023 / CLS Holdings USA, Inc. (OTCQB:CLSH)(CSE:CLSH), (the ''Company'' or ''CLS''), a…

1 year ago